From: 1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment
Baseline (Mean ± SD)
Post-RT (Mean ± SD)
p
IPSS score
5.4 ± 3.7
7 ± 4.5
0,07